Status: Recruiting
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD). Participants will receive TZP or placebo (PBO) daily on Days 2 - 7 during a 7-day inpatient stay at the research center to determine safety, pharmacokinetic (PK) assessment, and efficacy of TZP for OWS.
Participants needed: 40
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Proniras CorporationUpdated: Sep 17, 2026Locations: 1
Eligibility criteria
Male, female or non-binary, age 18 to 65 years of age at Screening. [+11]
Active psychosis or mania that is impairing insight, decision-making, perception... [+19]